Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Team Develops Anti-Infection Technology
Combat-related injuries have long plagued the military in part because of multidrug-resistant bacteria. Imagine being able to spray a compound fracture with microcapsules that deliver a drug to bolster the immune system, stopping infection before it starts.

FDA Grants Approval For Use Of RISPERDAL(R) CONSTA(R) As Both A Monotherapy And Adjunctive Therapy In The Maintenance Treatment Of Bipolar I Disorder
Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder.
News of the day
Prepared Patient: Managing Mental And Medical Illness
In her 1984 boot camp graduation photo, Adrienne Fitts is smiling. Her hair is neatly groomed, her Navy cap and dress whites are spotless and she is regulation fit and trim.
Medical Devices

HearAtLast To Launch Exclusive Groundbreaking Neuro-CompensatorTM Technology Hearing Aids From VitaSound

HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced that in keeping with its tradition of bringing innovative new products to consumers, the Company announces the unveiling of breakthrough hearing products based on the Neuro-Compensator™ algorithm technology from VitaSound Audio. The NEURO-COMPENSATOR™ hearing instruments are powered by the newest groundbreaking neuro-biological technology designed to optimize the auditory nerve output. Based on many years of research at McMaster University into the electrical signals that are transmitted to the brain by the auditory nerves in healthy and impaired ears, this patented technology is designed to significantly improve the perceived audio quality in hearing devices. Using standard audiometric test data, the algorithm engine derives a customized map of an individual"s auditory system and configures the hearing device to optimize auditory nerve output for that individual. Clarity of sound, perception of true pitch, and more normal perception of own voice are just some of the benefits noted by trial subjects. "Neuro-Compensation represents a unique Canadian story from research at McMaster University, development at VitaSound, to market launch at our retail locations in Wal-Mart Canada stores," said Matthew Sacco, CEO of HearAtLast. "This underscores our commitment to being first to bring innovative new technologies to consumers." Available first in Canada exclusively at selected HearAtLast locations in mid-April, products will be generally available throughout the chain by the end of May. About VitaSound VitaSound"s mission is to develop and bring to market hearing solutions that are unique and innovative, but also accessible and affordable, to enable all individuals to benefit from better communications and quality of life. We focus on total hearing healthcare which involves protection, preservation, care and improvement, all in the context of today"s active lifestyles. For more information on VitaSound Audio, Inc., please visit: http://www.vitasound.com HearAtLast


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009